Therapeutic options for infections due to vancomycin-resistant enterococci

Jiun-Ling Wang, Po Ren Hsueh

研究成果: Review article同行評審

44 引文 斯高帕斯(Scopus)


Background: Vancomycin-resistant enterococci (VRE) are an important cause of nosocomial infection occurring in critical care or immunocompromised patients. Objectives: To provide updated information about therapeutic options for VRE infection. Methods: MEDLINE, EMBASE, and the Cochrane Library were searched to identify in vitro susceptibility data of VRE isolates, randomized and non-randomized controlled trials, case series, and cohort studies of VRE therapy published before 31 July 2008. Results/conclusion: The updated in vitro susceptibility data for VRE show high resistance to ampicillin and aminoglycosides. Quinupristin-dalfopristin is limited by its lack of activity against vancomycin-resistant Enterococcus faealis and its musculoskeletal side effects. Emerging linezolid resistance has been reported to cause hospital spread and may be related to prolonged linezolid use. Quinupristindalfopristin resistance is usually linked to agricultural use of streptogramin. Nitrofurantoin and fosfomycin are alternatives in uncomplicated VRE urinary tract infection. Daptomycin and tigecycline have shown excellent potential for treating VRE infection.

頁(從 - 到)785-796
期刊Expert Opinion on Pharmacotherapy
出版狀態Published - 2009 4月 1

All Science Journal Classification (ASJC) codes

  • 藥理
  • 藥學(醫學)


深入研究「Therapeutic options for infections due to vancomycin-resistant enterococci」主題。共同形成了獨特的指紋。